New therapies including CAR-T, bispecific antibodies and dual-antibody immunotherapy are reshaping multiple myeloma care. Advances in genomic testing may also improve risk assessment and treatment decisions.
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
CAR T-cell therapy demonstrates near-98% response rates in multiple myeloma trials, but only 2.6% of eligible patients receive treatment. Black patients face substantially lower access, with structural and institutional barriers limiting availability of the specialized therapy.
CAR T-cell therapy is delivering unprecedented results for multiple myeloma patients, with CARTITUDE-1 trial data showing one-third of patients remaining progression-free for five years or more, raising the possibility of cure for some patients.
The Phase III MAJESTY study met its primary endpoint, showing significantly more people achieved complete remission at two years with Gazyva versus tacrolimus. If approved, Gazyva would be the first therapy specifically indicated for primary membranous nephropathy.
Clinical studies demonstrate GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss when combined with lifestyle changes, with patients achieving mean reductions of 14.9% body weight over 68 weeks.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03676361 |
To Evaluate the Renal Tubular Function Pre and Post Nephrectomy in Living Donors |
WITHDRAWN | PHASE4 |
| NCT01781819 |
(ARFI) Shear Velocity Imaging of the Kidneys in Pediatric Patients |
WITHDRAWN | NA |
